Literature DB >> 23032163

Maturation of morphology, phenotype and functions of murine bone marrow-derived dendritic cells (DCs) induced by polysaccharide Kureha (PSK).

Yonggang Tan1, Yiming Meng, Zuozhou Wang, Fengping Shan, Qiushi Wang, Ning Zhang.   

Abstract

The aim of this work was to evaluate the influence of protein-bound polysaccharide Kureha(PSK) on murine dendritic cells (DCs). These impacts of PSK on DCs from bone marrow derived DCs(BMDCs) were assessed with inverted phase contrast microscope, conventional scanning electron microscopy (SEM), transmission electron microscopy (TEM) for morphology, fluorescence activated cell sorting (FACS) analysis, cytochemistry assay for key surface molecules, FITC-dextran for phagocytosis, bio-assay and enzyme linked immunosorbent assay (ELISA) for cytokine production. We found that under the influence of PSK, immature DCs changed into mature DCs with decrease of antigens up-taking, simultaneously high expression of key surface molecules of the MHC classII,CD40, CD80, CD86 and CD83 as well as more production of IL-12p70 and tumor necrosis factor α (TNF-α). These data indicate that PSK could markedly promote maturation of DCs and this adjuvant-like activity may have potential therapeutic value in vaccine preparation.

Entities:  

Keywords:  bone marrow derived DCs; maturation; modulation; polysaccharide kureha

Mesh:

Substances:

Year:  2012        PMID: 23032163      PMCID: PMC3656070          DOI: 10.4161/hv.21993

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  40 in total

1.  Effect of polysaccharide krestin on glutathione peroxidase gene expression in mouse peritoneal macrophages.

Authors:  Z J Pang; Y Chen; M Zhou; J Wan
Journal:  Br J Biomed Sci       Date:  2000       Impact factor: 3.829

2.  Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

Authors:  P A Lodge; L A Jones; R A Bader; G P Murphy; M L Salgaller
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK.

Authors:  Anquan Liu; George Klein; Kentaro Bandobashi; Eva Klein; Noémi Nagy
Journal:  Immunol Lett       Date:  2002-03-01       Impact factor: 3.685

4.  Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age.

Authors:  Katharina Garbe; Kai Bratke; Stefanie Wagner; Johann Christian Virchow; Marek Lommatzsch
Journal:  Hum Immunol       Date:  2012-02-16       Impact factor: 2.850

5.  HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.

Authors:  Lorena Landuzzi; Agnese Antognoli; Giordano Nicoletti; Stefania Croci; Arianna Palladini; Marianna Lucia Ianzano; Annalisa Murgo; Valeria Stivani; Valentina Grosso; Patrizia Nanni; Carla De Giovanni; Pier-Luigi Lollini
Journal:  Vaccine       Date:  2011-05-11       Impact factor: 3.641

Review 6.  Polysaccharide-K (PSK) in cancer--old story, new possibilities?

Authors:  C Sun; A H Rosendahl; X D Wang; D Q Wu; R Andersson
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Acute and subchronic oral toxicity of Coriolus versicolor standardized water extract in Sprague-Dawley rats.

Authors:  Sook Yee Hor; Mariam Ahmad; Elham Farsi; Chung Pin Lim; Mohd Zaini Asmawi; Mun Fei Yam
Journal:  J Ethnopharmacol       Date:  2011-07-08       Impact factor: 4.360

8.  PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity.

Authors:  K Asai; H Kato; K Hirose; K Akaogi; S Kimura; S Mukai; M Inoue; Y Yamamura; H Sano; S Sugino; T Yoshikawa; M Kondo
Journal:  Immunopharmacol Immunotoxicol       Date:  2000-05       Impact factor: 2.730

Review 9.  The use of mushroom glucans and proteoglycans in cancer treatment.

Authors:  P M Kidd
Journal:  Altern Med Rev       Date:  2000-02

Review 10.  Are there new therapeutic options for treating lung cancer based on herbal medicines and their metabolites?

Authors:  Soo-Jin Jeong; Wonil Koh; Bonglee Kim; Sung-Hoon Kim
Journal:  J Ethnopharmacol       Date:  2011-10-18       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.